SCHEMBL2810388

SCHEMBL2810388

CCCCCC(=O)NS(C)(=O)=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.62
HSP90AA1 P07900 1/20 0.54
FAAH O00519 6/20 0.52
PTGES O14684 1/20 0.50
MEN1 O00255 1/20 0.48
MAPK1 P28482 1/20 0.48
KMT2A Q03164 1/20 0.48
CES2 O00748 4/20 0.46
CES1 P23141 4/20 0.46
AKR1B1 P15121 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43
GPR84 Q9NQS5 1/20 0.43
DNM1 Q05193 1/20 0.43
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13188006 0.98 EPHX2 (0.65) EPHX2HSP90AA1FAAHPTGESMEN1
SCHEMBL18954224 0.98 EPHX2 (0.65) EPHX2HSP90AA1FAAHPTGESMEN1
SCHEMBL6887420 0.93 EPHX2 (0.55) EPHX2HSP90AA1FAAHPTGESMEN1
Hydrochloric Acid SCHEMBL3354881 0.91 EPHX2 (0.54) EPHX2HSP90AA1FAAHPTGESMEN1
SCHEMBL18954312 0.88 EPHX2 (0.81) EPHX2FAAHMEN1KMT2APPARG
SCHEMBL6015 0.84 HDAC3 (0.50) EPHX2PTGESMEN1KMT2ACES2
SCHEMBL7180177 0.83 HSP90AA1 (0.54) EPHX2HSP90AA1FAAHMEN1MAPK1
SCHEMBL2807682 0.83 HSP90AA1 (0.54) EPHX2HSP90AA1FAAHMEN1MAPK1
SCHEMBL8784794 0.83 LMNA (0.48) EPHX2MEN1KMT2AAKR1B1ALDH1A1
SCHEMBL91016 0.81 TSHR (0.50) EPHX2MEN1KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4440702-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2024-10-09 EP disclosed
CN-118369325-A Therapeutic compounds for HIV virus infection 吉利德科学公司 2024-07-19 CN disclosed
WO-2023102239-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2023-06-08 WO disclosed
US-9627217-B2 Silicon-containing EUV resist underlayer film-forming composition including additive NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-04-18 US disclosed
US-9150556-B2 Benzimidazolone chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-06 US disclosed
US-20100240702-A1 Benzimidazolone Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240702-A1 Benzimidazolone Chymase Inhibitors CMA1, SERPINB1, CPA3 EPHX2 4039/4885HSP90AA1 1201/4885FAAH 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.